Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The host respiratory epithelial cell surface entry receptors and co-factors engaged by RSV F and G glycoproteins represent a diverse group of membrane-associated proteins that facilitate the infection cycle of Respiratory Syncytial Virus (RSV) (Reactome, 2023). The RSV G glycoprotein initiates the process by binding to attachment factors such as heparan sulfate proteoglycans (HSPGs) and the CX3C chemokine receptor 1 (CX3CR1), which is a key determinant of the virus's tropism for ciliated airway epithelial cells (Tripp et al., 2001; PLOS, 2015). Subsequently, the RSV F glycoprotein mediates membrane fusion by interacting with specific host receptors, most notably nucleolin (NCL) and the insulin-like growth factor 1 receptor (IGF1R) (Tayyari et al., 2011; Griffiths et al., 2020). IGF1R activation triggers a signaling cascade involving protein kinase C zeta (PKCζ) that recruits nucleolin from the nucleus to the apical cell surface, where it functions as a fusion receptor (Nature, 2020). Other co-factors, including the epidermal growth factor receptor (EGFR), intercellular adhesion molecule 1 (ICAM-1), and Toll-like receptor 4 (TLR4), further modulate viral entry, signaling, and the host inflammatory response (Currier et al., 2016; Frontiers, 2021). While current clinical interventions like palivizumab and nirsevimab target the viral F protein, these host factors are increasingly recognized as potential therapeutic targets for preventing or treating RSV-associated diseases such as bronchiolitis and pneumonia (ASM, 2024).
Inhibition of viral attachment and fusion by targeting viral glycoproteins or host cell surface receptors and their associated signaling pathways.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host respiratory epithelial cell surface entry receptors and co-factors engaged by RSV F and G glycoproteins.